To summarize the structure, biogenesis, and functional consequences of p53 isoforms and their expression in hematological malignancies, emphasizing their potential role in treatment response.
Key Findings:
p53 isoforms can differentially influence cell-cycle arrest, senescence, apoptosis, and DNA-damage responses, with implications for treatment outcomes.
N-terminally truncated isoforms and C-terminally spliced variants can modulate tetramer composition and transcriptional programs, affecting tumor behavior.
The clinical significance of p53 isoform patterns in hematological malignancies is not fully defined due to small and heterogeneous studies, necessitating further investigation.
Interpretation:
Comprehensive profiling of p53 isoforms may refine biological classification and risk assessment in hematological cancers, but requires standardized assays and validation to impact clinical practice.
Limitations:
Evidence derived from relatively small and methodologically heterogeneous studies, highlighting the need for diverse patient populations.
Need for standardized assays and larger, clinically annotated cohorts for validation.
Conclusion:
Further research is necessary to clarify the clinical utility of p53 isoform profiling in hematological malignancies, particularly in understanding their role in treatment response.
